Pharmaceutical company Cytochroma announced a repeat-dose safety and efficacy study of CTAP101 capsules in patients with vitamin D insufficiency, secondary hyperparathyroidism and stage III chronic kidney disease.

The trial is a randomized, double-blind, placebo-controlled, multi-site study evaluating the safety, efficacy, pharmacokinetics, pharmacodynamics and tolerability of CTAP101 capsules, administered at daily doses, in 60 patients. Study endpoints will include vitamin D status, adverse events, physical and clinical laboratory assessments and changes in serum calcium, phosphorus and intact parathyroid hormone.